| Literature DB >> 23762134 |
Tao Liu1, Li-Li Yang, Lu Zou, Dong-Fei Li, Hong-Zhu Wen, Pei-Yong Zheng, Lian-Jun Xing, Hai-Yan Song, Xu-Dong Tang, Guang Ji.
Abstract
Lingguizhugan decoction (LGZG), a classic traditional Chinese medicine (TCM) formula, has been used to treat obesity and hyperlipidemia in recent years, but the related mechanisms underlying the regulation of lipid metabolism by LGZG are not clear yet. Here, we reported the effectiveness and possible mechanisms of LGZG on rats with fatty liver disease induced by high-fat diet (HFD). Our results demonstrated that LGZG significantly attenuated HFD-induced fatty liver disease, as measured by body weight, liver index, epididymal fat pad-body weight ratio (EFP/BW), liver injury, and hepatic triglycerides (TG) probably through increasing serum thyroid hormone levels, improving beta-oxidation (via modulation of TR β 1 and CPT1A expression), metabolism and transport (through modulation of SREBP-1c, ACSL and ApoB100 expression) of fatty acid. In addition, we discovered the herbal combination with the properties of warming yang to relieve water retention in the formula and proposed the biological basis of LGZG conventional effect via further study on disassembled formula. This study, for the first time, revealed the mechanisms through which LGZG regulates lipid metabolism. Furthermore, our study suggested that it might be feasible to understand the scientific implications of TCM from the perspective of classic formulas' conventional efficacy.Entities:
Year: 2013 PMID: 23762134 PMCID: PMC3664975 DOI: 10.1155/2013/429738
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
List of primers.
| Gene | Forward primer | Reverse primer | Probe | NCBI RS* |
|---|---|---|---|---|
| TR | AATGGGGAAATGGCAGGAC | AAGACATCAGCAGGACGGC | CAGGGCAACCTCCGTGTCATCC | NM_012672.2 |
| CPT1A | ATCACTGGTGTGTTCCCCG | GATCTTTGCGATCATGCCC | ATGGATGAAATCACACCCACCACCA | NM_031559.2 |
| SREBP-1c | GCCATCGACTACATCCGCTT | CAGGTCTTTCAGTGATTTGCTTTT | CAGCACAGCAACCAGAAACTCAAGCA | XM_213329 |
| ApoB100 | GCATTCTAACTGCCGAGGG | CAAATGGTTGTGCCGAAAAG | CCATTTAAGTTGGCATTGTGCTCACCA | NM_019287.2 |
| ACSL | ATCTTCCCTGTGGTTCCGAG | TCTGACGATGCCACTGCG | CAAAATCCAACAGCCATCGCTTCAC | NM_012820.1 |
|
| AGGGAAATCGTGCGTGAC | CGCTCATTGCCGATAGTG | CTGTGCTATGTTGCCCTAGACTTC | NM_031144.2 |
*RS: reference sequence.
The influence of LGZG decoction and its decomposed recipes on rats' body weight, liver index, and EFP/BW (mean ± SD).
| Group |
| Body weight (gm) | Liver index (%) | EFP/BW (%) |
|---|---|---|---|---|
| Normal | 8 | 323.25 ± 15.50 | 3.39 ± 0.11 | 0.101 ± 0.007 |
| Model | 8 | 341.13 ± 11.99* | 4.44 ± 0.09* | 0.139 ± 0.008* |
| LGZG | 8 | 332.13 ± 17.47 | 4.21 ± 0.20# | 0.119 ± 0.010# |
| LZG | 8 | 344.75 ± 6.90 | 4.33 ± 0.11 | 0.129 ± 0.009 |
| GZG | 8 | 345.75 ± 13.14 | 4.33 ± 0.11 | 0.124 ± 0.016 |
| LG | 8 | 348.88 ± 17.23 | 4.27 ± 0.07# | 0.121 ± 0.007# |
*P < 0.05 versus normal group, # P < 0.05 versus model group.
Figure 1The influence of LGZG and its decomposed recipes on rats' histopathology (H&E stain ×200) and TG levels. (a) Normal group fed with chow diet; (b) model group fed with High-Fat Diet (HFD); (c) LGZG group fed with HFD and LGZG; (d) LZG group fed with HFD and LZG; (e) GZG group fed with HFD and GZG; (f) LG group fed with HFD and LG. (g) The influence of LGZG and its decomposed recipes on rats' hepatic TG. *P < 0.05 versus normal group, # P < 0.05 versus model group.
The influence of LGZG decoction and its decomposed recipes on serum transaminases and lipid levels (mean ± SD).
| Group |
| ALT (U/L) | AST (U/L) | TG (mmol/L) | TC (mmol/L) | HDL (mmol/L) | LDL (mmol/L) |
|---|---|---|---|---|---|---|---|
| Normal | 8 | 41.83 ± 4.38 | 113.28 ± 21.51 | 1.31 ± 0.43 | 1.48 ± 0.10 | 1.39 ± 0.11 | 0.12 ± 0.02 |
| Model | 8 | 44.18 ± 3.83 | 128.64 ± 9.91* | 1.24 ± 0.30 | 2.40 ± 0.22* | 1.12 ± 0.10* | 1.00 ± 0.19 |
| LGZG | 8 | 41.48 ± 3.10 | 105.41 ± 12.18# | 0.60 ± 0.16# | 2.00 ± 0.10# | 1.03 ± 0.05# | 0.94 ± 0.12 |
| LZG | 8 | 44.21 ± 3.56 | 118.10 ± 9.31 | 0.87 ± 0.13 | 2.18 ± 0.36 | 1.08 ± 0.08 | 1.00 ± 0.27 |
| GZG | 8 | 43.26 ± 4.60 | 103.90 ± 14.84# | 0.94 ± 0.23 | 2.46 ± 0.24 | 1.09 ± 0.08 | 1.16 ± 0.22 |
| LG | 8 | 40.90 ± 4.48 | 105.44 ± 10.25# | 0.55 ± 0.16# | 2.04 ± 0.13# | 1.03 ± 0.04# | 0.96 ± 0.11 |
*P < 0.05 versus normal group, # P < 0.05 versus model group.
The influence of LGZG decoction and its decomposed recipes on serum T3, FT3, T4, and FT4 (mean ± SD).
| Group |
| T3 (nmol/L) | FT3 (nmol/L) | T4 (nmol/L) | FT4 (nmol/L) |
|---|---|---|---|---|---|
| Normal | 8 | 1.02 ± 0.08 | 4.65 ± 0.61 | 73.59 ± 5.66 | 38.44 ± 2.12 |
| Model | 8 | 0.96 ± 0.08 | 4.06 ± 0.49* | 54.97 ± 3.60* | 28.38 ± 2.39* |
| LGZG | 8 | 1.05 ± 0.06# | 4.56 ± 0.39# | 66.73 ± 2.58# | 33.76 ± 1.88# |
| LZG | 8 | 0.97 ± 0.07 | 4.04 ± 0.43 | 58.73 ± 4.67 | 30.31 ± 2.82 |
| GZG | 8 | 1.00 ± 0.10 | 4.48 ± 0.56 | 59.35 ± 3.05# | 29.31 ± 1.66 |
| LG | 8 | 1.10 ± 0.05# | 5.13 ± 0.30# | 70.23 ± 4.10# | 35.33 ± 1.93# |
*P < 0.05 versus normal group, # P < 0.05 versus model group.
Figure 2LGZG improved fatty acid beta-oxidation via regulation of TRβ1 and CPT1A expression. The relative mRNA and protein expression of TRβ1 and CPT1A were detected by real-time PCR and western blot. (a) The influence of LGZG and its decomposed recipes on the protein expression of hepatic TRβ1 and CPT1A; (b) the influence of LGZG and its decomposed recipes on the relative mRNA of hepatic TRβ1 and CPT1A (normalized by β-actin). *P < 0.05 versus normal group, # P < 0.05 versus model group.
Figure 3LGZG enhanced metabolism and transport of fatty acid through modulation of SREBP-1c, ACSL and ApoB100 expression. The relative mRNA and protein expression of SREBP-1c, ACSL, and ApoB100 were detected by real-time PCR and western blot. (a) The influence of LGZG and its decomposed recipes on the protein expression of hepatic SREBP-1c and ACSL; (b)–(d) the influence of LGZG and its decomposed recipes on the relative mRNA of hepatic SREBP-1c, ACSL, and ApoB100 (normalized by β-actin). *P < 0.05 versus normal group, # P < 0.05 versus model group.